로딩 중…
지수 로딩 중…
KANGSTEM BIOTECH CO., LTD.
217730· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,190+3.79%
2026-08-04
Financials
Valuation Metrics
KANGSTEM BIOTECH CO., LTD.'s Market Cap is ₩2060B. At end of 2025 it was ₩2182B. Ranked #804 of 2,436 in KR market (top 33%), #364 of 1,649 on KOSDAQ (top 22%), #87 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 205.98B KRW | KR#804/2,436 Sec#87/234 |
| Revenue | 3.42B KRW | KR#2,370/2,436 Sec#205/234 |
| Net Income | 4.04B KRW | KR#1,195/2,436 Sec#81/234 |
| Total Assets | 74.45B KRW | KR#1,949/2,436 Sec#164/234 |
| Net Assets | 62.25B KRW | KR#1,722/2,436 Sec#149/234 |
| Employees | 95 | KR#1,663/2,436 Sec#130/234 |
| Value | ||
| P/E | 51.00x | KR#1,357/2,436 Sec#88/234 |
| P/B | 3.31x | KR#2,147/2,436 Sec#172/234 |
| P/S | 60.17x | KR#2,374/2,436 Sec#200/234 |
| FCF Yield | -5.99% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 6.49% | KR#848/2,436 Sec#66/234 |
| ROA | 5.42% | KR#605/2,436 Sec#46/234 |
| Op. Margin | -511.02% | KR#2,377/2,436 Sec#210/234 |
| Revenue Growth | -15.65% | KR#1,995/2,436 Sec#181/234 |
| Financial Health | ||
| Debt Ratio | 119.60% | KR#645/2,436 Sec#82/234 |
| Total Debt | 7.77B KRW | KR#1,695/2,436 Sec#158/234 |
| FCF | -12.34B KRW | KR#1,771/2,436 Sec#156/234 |
| Cash | 1.12B KRW | KR#2,329/2,436 Sec#223/234 |
| Current Ratio | 4.56x | KR#333/2,436 Sec#63/234 |
| Performance | ||
| 1Y Return | 61.03% | KR#191/2,436 Sec#17/234 |
| 1M Return | -15.77% | KR#2,048/2,436 Sec#203/234 |
| From 52W High | -53.30% | KR#1,352/2,436 Sec#114/234 |
| 1Y MDD | -57.77% | KR#1,295/2,436 Sec#106/234 |
| Trading | ||
| Volume | 604,247 shares | KR#231/2,436 Sec#19/234 |
| Foreign Own. | 2.35% | KR#1,057/2,436 Sec#104/234 |
| Per Share | ||
| EPS | -252 KRW | KR—/2,436 Sec—/234 |
| BPS | 662 KRW | KR#2,363/2,436 Sec#224/234 |
Company Info
동사는 2010년 줄기세포치료제 개발 및 제조를 목적으로 설립되어 2015년 코스닥시장에 상장하였음. 제대혈 유래 줄기세포를 고순도로 분리하고 대량배양하는 원천기술을 보유하고 있으며, 주요 파이프라인으로 퓨어스템-에이디 주(아토피 피부염), 퓨어스템-알에이 주(류마티스 관절염), 오스카(골관절염 치료제)를 개발중임. 줄기세포 배양액 기반 화장품 사업도 영위하며 온라인 유통망을 강화하고 있음. 강스템바이오텍는 2010년에 설립되었으며 서울특별시 강남구에 본사를 두고 있습니다.